Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain
Crossref DOI link: https://doi.org/10.1186/s12955-017-0749-y
Published Online: 2017-10-17
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Weil, Arnold J.
Masters, Elizabeth T.
Barsdorf, Alexandra I.
Bass, Almasa
Pixton, Glenn
Wilson, Jacquelyn G.
Wolfram, Gernot
Funding for this research was provided by:
Pfizer